Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Associated Press/Washington Post examine contributions of military research to reducing global disease burden

In light of the U.S. Army's announcement yesterday that an experimental HIV vaccine trial it is sponsoring in Thailand showed modest potential for preventing infection, the Associated Press/Washington Post examines how military research is contributing to the fight against major diseases around the world.

25 Sep 2009

Collaboration for the evaluation of peptide copolymer technology

Peptimmune, Inc., a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

25 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

Study reveals that daily commuting may lead to mosquito-borne diseases

University of Hawaii at Manoa assistant researcher Durrell Kapan recently published a paper, Man Bites Mosquito: Understanding the Contribution of Human Movement to Vector-Borne Disease Dynamics, in PLoS One. Published August 26, the paper highlights how daily commuting patterns in mega-cities may be a critically overlooked factor in understanding the resurgence of mosquito-borne diseases such as dengue fever, infecting 50-100 million people annually.

21 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).

5 Sep 2009

Lancet examines dengue fever in Mexico

Lancet World Report examines the factors contributing to a steady uptick in the number of dengue fever cases in Mexico over the past decade. Compared to the year 2000, when "there were 1,781 reported cases … Last year, the number totalled 33,000, according to Mexico's Public Health Department. And confirmed cases this year have already surpassed 2008 figures by 15%," according to the journal.

24 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

Developed countries must address global warming to prevent disease, hunger in developing world

Pollution from the world's wealthiest countries is spreading disease and hunger in developing countries, according to a new Oxfam International report, which calls on developed countries to address global warming when G8 leaders meet in Italy, the Globe and Mail reports.

7 Jul 2009

Communicable disease epidemics in developing world not being adequately addressed, IFRC says

The "crippling" and "growing burden" of communicable diseases such as dengue fever, polio, or meningitis is not being sufficiently addressed in developing countries, according to "The Epidemic Divide," a report released Monday by the International Federation of Red Cross and Red Crescent Societies (IFRC), AFP/Google.com reports. According to the report, resources to deal with existing epidemics are "scarce."

7 Jul 2009

Newsweek, Boston Globe examine ways to combat mosquito-borne illness

Newsweek examines the genetic modification of mosquitoes in an effort to stem the spread of dengue fever and malaria. Dengue fever, which is transmitted by the Aedes Aegypti mosquito, "is spreading fast," according to the magazine, with more than 100 million people afflicted yearly. "There is no vaccine, no cure and no solution," it reports.

30 Jun 2009

Distributed drug discovery for neglected diseases

Researchers from Indiana University-Purdue University Indianapolis (IUPUI) have developed Distributed Drug Discovery (D3), a new low-cost strategy to accelerate the discovery of drugs to treat neglected diseases such as tuberculosis, leprosy, leshmaniasis, dengue fever, and Chagas disease.

16 Jun 2009

Philippines Health Secretary warns of impending Dengue threat

With the start of the rainy season, Francisco Duque III, health secretary in the Philippines, on Tuesday emphasized a continued government commitment to controlling and preventing dengue - a disease for which there is currently no vaccine or specific drug, the Manila Times reports.

10 Jun 2009

New York Times examines varying definitions of 'pandemic'

"The new swine influenza virus [H1N1], which appeared suddenly after years of warning about a potential pandemic of avian influenza, upset the WHO's assumptions that most people have the same understanding of the word pandemic," says the New York Times in a report that examines the difficultly health experts have had when attempting to agree upon what constitutes a pandemic.

9 Jun 2009

Scientists use climate variables and vegetation indices to predict and mitigate Dengue epidemics

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are the most important vector-borne viral diseases in the World. Around 50-100 million cases appear each year putting 2.5 billion people at risk of suffering this debilitating and sometimes fatal disease.

5 Jun 2009

Money from Bill and Melinda Gates will help beat Dengue fever in Australia

The University of Queensland (UQ) has won a grant of $100,000 grant from the Bill and Melinda Gates Foundation to fight dengue and other mosquito-borne diseases.

11 May 2009

New research nets the true economic costs of dengue fever

Researchers at Brandeis, in collaboration with several other institutions worldwide, have pinpointed for the first time the multi-country economic costs of dengue fever, the endemic and epidemic mosquito-borne illness that is a rapidly growing public health problem in tropical and sub-tropical countries.

7 May 2009

Dengue fever may be more of a worry to Australians than swine flu

For the last week or so much of the world's media has been gripped by the new influenza A H1N1 (swine flu) virus which has dominated the headlines everywhere.

6 May 2009